Mylan Wins Argument In Exclusivity Case, But Not Terazosin Approval
Executive Summary
Mylan will have to wait until after Feb. 9 to launch its generic terazosin capsules even though the company has won a federal court ruling that Geneva's 180-day exclusivity for the product should have already expired.
You may also be interested in...
Barr Fluoxetine Generic Exclusivity Claim Faces Hurdles
Barr's claim to 180 days of generic exclusivity for fluoxetine will depend on the outcome of judicial and regulatory proceedings over the next year.
Barr Fluoxetine Generic Exclusivity Claim Faces Hurdles
Barr's claim to 180 days of generic exclusivity for fluoxetine will depend on the outcome of judicial and regulatory proceedings over the next year.
FDA Ordered To Rescind Barr's 180-Day Exclusivity For Generic Tamoxifen
FDA is ordered to reverse its March 1999 decision to grant Barr's tamoxifen 180-day exclusivity by Washington, D.C. federal court on the grounds that Barr lost its first ANDA filer status when it dropped its patent challenge in a settlement with tamoxifen innovator AstraZeneca.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: